Johns Hopkins Diabetes GuideManagementType 1 Diabetes

Immunomodulating Therapies in Type 1 Diabetes

Clare J. Lee, M.D., Thomas Donner, M.D.
Immunomodulating Therapies in Type 1 Diabetes is a topic covered in the Johns Hopkins Diabetes Guide.

To view the entire topic, please or purchase a subscription.

Johns Hopkins Guides provide diagnosis, management, and treatment guidance for infectious diseases, diabetes, and psychiatric conditions. Explore these free sample topics:

Johns Hopkins Guides

~~ The first section of this topic is shown below ~~

DEFINITION

  • Type 1 diabetes mellitus (T1DM) is an autoimmune disease.
  • Destruction of insulin producing beta-cells by T cells renders patients insulin-deficient.
  • Exogenous insulin is therefore required for T1DM management of hyperglycemia and to prevent ketoacidosis [4].
  • Several immunomodulating therapies have been investigated in research studies over the last decades with the goal of preventing, postponing or reversing the onset of T1DM by slowing or stopping the immune-mediated destruction of beta-cells.

~~ To view the remaining sections of this topic, please
or purchase a subscription ~~

Last updated: July 11, 2013